/VCEL
VCEL Stock - Vericel Corporation
Healthcare|BiotechnologyNASDAQ
$36.05-0.30%
$0.11 (-0.30%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.35
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).89
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+19.3%upside
Target: $43.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VCEL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$35.69 – $36.41
TARGET (TP)$43.00
STOP LOSS$33.17
RISK/REWARD1:2.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.20
52W High$63.00
52W Low$29.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $237.22M | $197.52M | $164.37M | $156.18M | $124.18M |
| Gross Profit | $172.11M | $135.58M | $109.79M | $106.03M | $84.23M |
| Gross Margin | 72.6% | 68.6% | 66.8% | 67.9% | 67.8% |
| Operating Income | $4.52M | $-6,464,000 | $-17,058,000 | $-7,854,000 | $2.37M |
| Net Income | $10.36M | $-3,182,000 | $-16,709,000 | $-7,471,000 | $2.86M |
| Net Margin | 4.4% | -1.6% | -10.2% | -4.8% | 2.3% |
| EPS | $0.21 | $-0.07 | $-0.35 | $-0.16 | $0.06 |
Company Overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
57%
Hold / Neutral
3
43%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish3 Neutral/Bearish
Price Targets
$48
Average Target
↑ 34.3% Upside
Now
$39
Low
$48
Average
$57
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 17th 2025 | BTIG Research | Downgrade | Neutral | - |
| August 9th 2024 | Canaccord Genuity | Initiation | Buy | $57 |
| June 20th 2024 | TD Cowen | Initiation | Buy | $55 |
| January 25th 2024 | Truist | Upgrade | Buy | $51← $39 |
| August 8th 2023 | BTIG Research | Upgrade | Buy | $39 |
| November 10th 2022 | BTIG Research | Downgrade | Neutral | - |
| November 9th 2022 | Truist | Downgrade | Hold | - |
| October 14th 2022 | Stephens | Resumed | Overweight | $40 |
Earnings History & Surprises
VCELBeat Rate
50%
Last 18 quarters
Avg Surprise
+28.6%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$0.10
Q4 2025
EPS Surprise History
Q1 24
+52.9%
$0.26vs$0.17
Q2 24
+27.3%
$-0.08vs$-0.11
Q3 24
0.0%
$-0.10vs$-0.10
Q4 24
+60.0%
$-0.02vs$-0.05
Q1 25
+22.6%
$0.38vs$0.31
Q2 25
-155.6%
$-0.23vs$-0.09
Q3 25
+75.0%
$-0.01vs$-0.04
Q4 25
+600.0%
$0.10vs$-0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.45 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.02 | $0.10 | +600.0% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.04 | $-0.01 | +75.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.09 | $-0.23 | -155.6% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.31 | $0.38 | +22.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.05 | $-0.02 | +60.0% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2024 | May 8, 2024 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.17 | $0.26 | +52.9% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.13 | $-0.08 | +38.5% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.13 | $-0.16 | -23.1% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $0.04 | $0.12 | +239.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-0.13 | $-0.19 | -46.2% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.15 | $-0.15 | 0.0% | = MET |
Q1 2022 | Feb 24, 2022 | $0.14 | $0.09 | -35.7% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.03 | $-0.11 | -305.3% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.06 | $-0.08 | -33.3% | ✗ MISS |
Latest News
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $45
📈 PositiveBenzinga•Dec 18, 2025, 04:10 PM
Truist Securities Reiterates Buy on Vericel, Raises Price Target to $50
📈 PositiveBenzinga•Nov 10, 2025, 05:17 PM
Vericel shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 6, 2025, 05:20 PM
Vericel Lowers FY2025 Sales Guidance from $284.669M-$291.786M to $272.000M-$276.000M vs $275.258M Est
📉 NegativeBenzinga•Nov 6, 2025, 12:57 PM
Vericel Q3 EPS $0.10 Beats $(0.01) Estimate, Sales $67.503M Beat $64.563M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:55 PM
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $41
📈 PositiveBenzinga•Oct 15, 2025, 04:20 PM
BTIG Downgrades Vericel to Neutral
➖ NeutralBenzinga•Sep 17, 2025, 10:07 AM
Frequently Asked Questions about VCEL
What is VCEL's current stock price?
Vericel Corporation (VCEL) is currently trading at $36.05 per share. The stock has moved -0.30% today.
What is the analyst price target for VCEL?
The average analyst price target for VCEL is $43.00, based on 1 analyst.
What sector is Vericel Corporation in?
Vericel Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VCEL's market cap?
Vericel Corporation has a market capitalization of $1.82 billion, making it a small-cap company.
Does VCEL pay dividends?
No, Vericel Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAUPH
Aurinia Pharmaceuticals Inc.
$16.18
Mkt Cap: $2.1B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
MNKD
MannKind Corporation
$5.84
Mkt Cap: $1.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to VCEL for comparison